Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

198 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The CADM1 tumor suppressor gene is a major candidate gene in MDS with deletion of the long arm of chromosome 11.
Lafage-Pochitaloff M, Gerby B, Baccini V, Largeaud L, Fregona V, Prade N, Juvin PY, Jamrog L, Bories P, Hébrard S, Lagarde S, Mansat-De Mas V, Dovey OM, Yusa K, Vassiliou GS, Jansen JH, Tekath T, Rombaut D, Ameye G, Barin C, Bidet A, Boudjarane J, Collonge-Rame MA, Gervais C, Ittel A, Lefebvre C, Luquet I, Michaux L, Nadal N, Poirel HA, Radford-Weiss I, Ribourtout B, Richebourg S, Struski S, Terré C, Tigaud I, Penther D, Eclache V, Fontenay M, Broccardo C, Delabesse E. Lafage-Pochitaloff M, et al. Among authors: bories p. Blood Adv. 2022 Jan 25;6(2):386-398. doi: 10.1182/bloodadvances.2021005311. Blood Adv. 2022. PMID: 34638130 Free PMC article.
NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis.
Struski S, Lagarde S, Bories P, Puiseux C, Prade N, Cuccuini W, Pages MP, Bidet A, Gervais C, Lafage-Pochitaloff M, Roche-Lestienne C, Barin C, Penther D, Nadal N, Radford-Weiss I, Collonge-Rame MA, Gaillard B, Mugneret F, Lefebvre C, Bart-Delabesse E, Petit A, Leverger G, Broccardo C, Luquet I, Pasquet M, Delabesse E. Struski S, et al. Among authors: bories p. Leukemia. 2017 Mar;31(3):565-572. doi: 10.1038/leu.2016.267. Epub 2016 Oct 3. Leukemia. 2017. PMID: 27694926
Outcome of relapsed/refractory AML patients with IDH1R132 mutations in real life before the era of IDH1 inhibitors.
Largeaud L, Bertoli S, Bérard E, Dufrechou S, Prade N, Gadaud N, Tavitian S, Bories P, Luquet I, Sarry A, Mas V, Huguet F, Delabesse E, Récher C. Largeaud L, et al. Among authors: bories p. Leuk Lymphoma. 2020 Feb;61(2):473-476. doi: 10.1080/10428194.2019.1668937. Epub 2019 Sep 30. Leuk Lymphoma. 2020. PMID: 31566052 No abstract available.
CD34+CD38-CD123+ Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents.
Vergez F, Nicolau-Travers ML, Bertoli S, Rieu JB, Tavitian S, Bories P, Luquet I, Mas V, Largeaud L, Sarry A, Huguet F, Delabesse E, Bérard E, Récher C. Vergez F, et al. Among authors: bories p. Cancers (Basel). 2020 May 6;12(5):1174. doi: 10.3390/cancers12051174. Cancers (Basel). 2020. PMID: 32384744 Free PMC article.
Dactinomycin in acute myeloid leukemia with NPM1 mutations.
Beziat G, Tavitian S, Bertoli S, Huguet F, Largeaud L, Luquet I, Vergez F, Rieu JB, Bories P, Delabesse E, Récher C. Beziat G, et al. Among authors: bories p. Eur J Haematol. 2020 Sep;105(3):302-307. doi: 10.1111/ejh.13438. Epub 2020 May 25. Eur J Haematol. 2020. PMID: 32452083
Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine.
Bories P, Prade N, Lagarde S, Cabarrou B, Largeaud L, Plenecassagnes J, Luquet I, De Mas V, Filleron T, Cassou M, Sarry A, Fornecker LM, Simand C, Bertoli S, Recher C, Delabesse E. Bories P, et al. PLoS One. 2020 Oct 1;15(10):e0238795. doi: 10.1371/journal.pone.0238795. eCollection 2020. PLoS One. 2020. PMID: 33001991 Free PMC article.
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.
Vercellino L, Di Blasi R, Kanoun S, Tessoulin B, Rossi C, D'Aveni-Piney M, Obéric L, Bodet-Milin C, Bories P, Olivier P, Lafon I, Berriolo-Riedinger A, Galli E, Bernard S, Rubio MT, Bossard C, Meignin V, Merlet P, Feugier P, Le Gouill S, Ysebaert L, Casasnovas O, Meignan M, Chevret S, Thieblemont C. Vercellino L, et al. Among authors: bories p. Blood Adv. 2020 Nov 24;4(22):5607-5615. doi: 10.1182/bloodadvances.2020003001. Blood Adv. 2020. PMID: 33180899 Free PMC article.
198 results